Blockchain could be one solution to the saleable returns verification aspect of the US’ Drug Supply Chain Security Act.
Heather Zenk |
In my view, one of the most exciting aspects of blockchain is its potential to revolutionize the way the pharmaceutical industry exchanges data. Electronic medical records, clinical trial management, supply chain, and scientific data sharing could all benefit from a distributed blockchain system, where data is managed by a cluster of computers, rather than any single entity.
One example of blockchain’s applicability in the pharma industry is the Drug Supply Chain Security Act (DSCSA) Saleable Returns Verification requirement in the US. By November 27, 2019, when a pharmacy returns a product, the distributor will be required to verify that the serial number on the bottle is the same as the serial number the manufacturer applied to the package, before it can be restocked and resold. In today’s environment, the distributor would have to connect with a manufacturer on a one-to-one basis. I work on behalf of AmerisourceBergen, which works with 450-plus pharmaceutical manufacturers. With our existing systems, the new requirement would mean taking the serialized bottle from a pharmacy, scanning it to assess which manufacturer it belongs to, and then asking them whether the serial number is valid – for 15 million units. A mammoth task!
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.